MarketInOut Stock Screener Log In | Sign Up
 

Arcus Biosciences Inc

NYSE • Healthcare • Biotechnology • Quote as of 09/18/2026
Arcus Biosciences Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization3,058.8 mln
Float78.00 mln
Earnings Date11/10/2026

Beneish M-Score

0.48
Highly suspicious

1-Year Forecast

38.75
Exceptional upside

Relative Strength

2 / 100
Severely lagging

Debt / Equity

0.25
Very low leverage

Pre-Tax Margin

-393%
Severely loss-making

ROE

-88.33
Deeply negative

Business Description

Arcus Biosciences is a California-based company founded in 2015 that focuses on developing new treatments for cancer. Its pipeline includes several drug candidates targeting different cancer types, including kidney, lung, gastrointestinal, and pancreatic cancers, with many currently in clinical trials. The company works alongside partners such as AstraZeneca to advance key studies and also conducts research into treatments for inflammatory diseases.

Key Fundamentals

EPS-3.98
ROE-88.33
RPS0.98
ROIC-232
ROA-45.02
Interest Cover-21.13
EBITDA, mln-439
EV / EBITDA-7.13
EV / EBIT-6.97
Revenue, mln117
EV / Revenue26.76

Quote Details

Last 25.24
Change -0.3 (-1.17%)
Open 25.74
Volume 2,897,075
Turnover 73,122,176
Average Volume 1,564,448

Financial Ratios

Pre-Tax Profit Margin-393
Leverage Ratio1.99
Current Ratio3.82
Price / Book7.99
Price / Tangible Book8.00
Debt / Equity0.25
Price / Sales29.72

Financial Strength

Altman Z-Score1.52
Beneish M-Score0.48
1-Year Target Price38.75
Short Ratio11.21
Short % of Float16.76

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 2.64% 93 / 100   
1 Month -16.84% 5 / 100   
2 Months 8.33% 84 / 100   
6 Months 12.53% 68 / 100   
1 Year 110% 98 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us